NCT05249374View on ClinicalTrials.gov

Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 14, 2021

Primary Completion Date

May 16, 2022

Study Completion Date

May 16, 2022

Conditions
Hepatic Ascites
Interventions
DRUG

Recombinant Human Serum Albumin

10 g/bottle (20%, 50 mL)

DRUG

Human serum albumin

10 g/bottle (20%, 50 mL)

Trial Locations (1)

100084

Shenzheng Protgen Ltd, Guangdong

All Listed Sponsors
lead

Protgen Ltd

INDUSTRY

NCT05249374 - Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects | Biotech Hunter | Biotech Hunter